Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CDA | P32320 | 1/20 | 0.50 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.49 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.49 |
| ▸ | TYMP | P19971 | 1/20 | 0.47 |
| ▸ | PYGM | P11217 | 3/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31685622 | 0.85 | MAPT (0.51) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL16781797 | 0.85 | MAPT (0.51) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL11665141 | 0.85 | MAPT (0.48) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL7764746 | 0.85 | MAPT (0.51) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL9251595 | 0.85 | TYMP (0.48) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL17114013 | 0.85 | TYMP (0.48) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL22408740 | 0.84 | LMNA (0.47) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL5975040 | 0.84 | PYGM (0.49) | MAPTCDASLC28A1SLC28A2SLC29A1 | |
| SCHEMBL23883568 | 0.81 | KDM4E (0.49) | MAPTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL31620041 | 0.80 | SLC28A1 (0.45) | MAPTCDASLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2030974-B1 | THIAZOLE NON-NUCLEOSIDE COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITION AND THEIR USE AS ANTIVIRAL AGENTS | SHANGHAI INST MATERIA MEDICA (CN) | 2016-02-17 | — | — | EP | disclosed |
| US-8653115-B2 | Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2014-02-18 | — | — | US | disclosed |
| EP-2218720-B1 | 2-2'-Bis-thiazole derivatives as antiviral agents | SHANGHAI INST MATERIA MEDICA (CN) | 2013-01-09 | — | — | EP | disclosed |
| EP-2223921-B1 | 2-Thiophen-2-yl-oxazole, 2-Thiophen-2-yl-thiazole and 2-Thiophen-2-yl-1H-imidazole derivatives as antiviral agents | SHANGHAI INST MATERIA MEDICA (CN) | 2013-01-09 | — | — | EP | disclosed |
| EP-2223921-A1 | 2-Thiophen-2-yl-oxazole, 2-Thiophen-2-yl-thiazole and 2-Thiophen-2-yl-1H-imidazole derivatives as antiviral agents | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2010-09-01 | — | — | EP | disclosed |
| EP-2218720-A1 | 2-2'-Bis-thiazole derivatives as antiviral agents | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2010-08-18 | — | — | EP | disclosed |
| US-7741348-B2 | Bisheterocycle tandem compounds useful as antiviral agents, the uses thereof and the compositions comprising such compounds | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2010-06-22 | — | — | US | disclosed |
| US-20100056569-A1 | Heterocyclic Non-Nucleoside Compounds, Their Preparation, Pharmaceutical Composition And Their Use As Antiviral Agents | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2010-03-04 | — | — | US | disclosed |
| EP-2030974-A1 | HETEROCYCLIC NON-NUCLEOSIDE COMPOUNDS, THEIR PEPARATION, PHARMACEUTICAL COMPOSITION AND THEIR USE AS ANTIVIRAL AGENTS | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2009-03-04 | — | — | EP | disclosed |
| US-20080306121-A1 | Bisheterocycle Tandem Compounds Useful as Antiviral Agents, the Uses Thereof and the Compositions Comprising Such Compounds | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2008-12-11 | — | — | US | disclosed |
| EP-1889843-A1 | BISHETEROCYCLE TANDEM COMPOUNDS USEFUL AS ANTIVIRAL AGENTS, THE USES THEREOF AND THE COMPOSITIONS COMPRISING SUCH COMPOUNDS | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056569-A1 | Heterocyclic Non-Nucleoside Compounds, Their Preparation, Pharmaceutical Composition And Their Use As Antiviral Agents | TYMP, PNP, NUDT1 | MAPT 1932/4885CDA 86/4885SLC28A1 354/4885 |
| US-20080306121-A1 | Bisheterocycle Tandem Compounds Useful as Antiviral Agents, the Uses Thereof and the Compositions Comprising Such Compounds | PCNA, HAVCR2, HCCS | MAPT 4539/4885CDA 514/4885SLC28A1 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.